AR045683A1 - Derivados de bencimidazol como inhibidores del factor xa - Google Patents
Derivados de bencimidazol como inhibidores del factor xaInfo
- Publication number
- AR045683A1 AR045683A1 ARP040101695A ARP040101695A AR045683A1 AR 045683 A1 AR045683 A1 AR 045683A1 AR P040101695 A ARP040101695 A AR P040101695A AR P040101695 A ARP040101695 A AR P040101695A AR 045683 A1 AR045683 A1 AR 045683A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- mono
- unsubstituted
- alkylene
- trisubstituted independently
- Prior art date
Links
- 108010074860 Factor Xa Proteins 0.000 title abstract 5
- 239000003112 inhibitor Substances 0.000 title abstract 2
- -1 pyridoimidazolyl Chemical group 0.000 abstract 34
- 125000000217 alkyl group Chemical group 0.000 abstract 12
- 125000002947 alkylene group Chemical group 0.000 abstract 12
- 125000003118 aryl group Chemical group 0.000 abstract 12
- 125000000623 heterocyclic group Chemical group 0.000 abstract 9
- 125000002619 bicyclic group Chemical group 0.000 abstract 8
- 125000002950 monocyclic group Chemical group 0.000 abstract 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 7
- 125000004122 cyclic group Chemical group 0.000 abstract 7
- 229910052736 halogen Inorganic materials 0.000 abstract 7
- 125000005842 heteroatom Chemical group 0.000 abstract 7
- 229910052757 nitrogen Inorganic materials 0.000 abstract 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 7
- 229910052760 oxygen Chemical group 0.000 abstract 7
- 239000001301 oxygen Chemical group 0.000 abstract 7
- 229910052717 sulfur Inorganic materials 0.000 abstract 7
- 239000011593 sulfur Chemical group 0.000 abstract 7
- 150000002367 halogens Chemical class 0.000 abstract 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 4
- 108010054265 Factor VIIa Proteins 0.000 abstract 4
- 229940012414 factor viia Drugs 0.000 abstract 4
- 125000001544 thienyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 2
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 abstract 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 abstract 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 abstract 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 abstract 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 abstract 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 abstract 2
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 abstract 2
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 abstract 2
- 125000001041 indolyl group Chemical group 0.000 abstract 2
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 abstract 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 abstract 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 abstract 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 abstract 2
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 abstract 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 abstract 1
- 125000004529 1,2,3-triazinyl group Chemical group N1=NN=C(C=C1)* 0.000 abstract 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 abstract 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 abstract 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 abstract 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 abstract 1
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 abstract 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 abstract 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 abstract 1
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 abstract 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 abstract 1
- 125000000164 1,3-thiazinyl group Chemical group S1C(N=CC=C1)* 0.000 abstract 1
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 abstract 1
- 125000005962 1,4-oxazepanyl group Chemical group 0.000 abstract 1
- 125000000183 1,4-thiazinyl group Chemical group S1C(C=NC=C1)* 0.000 abstract 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 abstract 1
- 125000005955 1H-indazolyl group Chemical group 0.000 abstract 1
- XWIYUCRMWCHYJR-UHFFFAOYSA-N 1h-pyrrolo[3,2-b]pyridine Chemical compound C1=CC=C2NC=CC2=N1 XWIYUCRMWCHYJR-UHFFFAOYSA-N 0.000 abstract 1
- 125000002471 4H-quinolizinyl group Chemical group C=1(C=CCN2C=CC=CC12)* 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000001435 Thromboembolism Diseases 0.000 abstract 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000002785 anti-thrombosis Effects 0.000 abstract 1
- 125000005602 azabenzimidazolyl group Chemical group 0.000 abstract 1
- 125000002785 azepinyl group Chemical group 0.000 abstract 1
- 125000002393 azetidinyl group Chemical group 0.000 abstract 1
- 125000004069 aziridinyl group Chemical group 0.000 abstract 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 abstract 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 abstract 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 abstract 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 1
- 230000023555 blood coagulation Effects 0.000 abstract 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 abstract 1
- 125000004623 carbolinyl group Chemical group 0.000 abstract 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000003838 furazanyl group Chemical group 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000002632 imidazolidinyl group Chemical group 0.000 abstract 1
- 125000002636 imidazolinyl group Chemical group 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 abstract 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 abstract 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 abstract 1
- 125000005438 isoindazolyl group Chemical group 0.000 abstract 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 abstract 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 abstract 1
- 125000005969 isothiazolinyl group Chemical group 0.000 abstract 1
- 125000001786 isothiazolyl group Chemical group 0.000 abstract 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 abstract 1
- 125000003971 isoxazolinyl group Chemical group 0.000 abstract 1
- 125000000842 isoxazolyl group Chemical group 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 abstract 1
- 125000004930 octahydroisoquinolinyl group Chemical group C1(NCCC2CCCC=C12)* 0.000 abstract 1
- 125000001715 oxadiazolyl group Chemical group 0.000 abstract 1
- 125000000160 oxazolidinyl group Chemical group 0.000 abstract 1
- 125000005968 oxazolinyl group Chemical group 0.000 abstract 1
- 125000002971 oxazolyl group Chemical group 0.000 abstract 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 abstract 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 abstract 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 abstract 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 abstract 1
- 125000005954 phenoxathiinyl group Chemical group 0.000 abstract 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 abstract 1
- 125000003884 phenylalkyl group Chemical group 0.000 abstract 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 abstract 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 abstract 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 abstract 1
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 abstract 1
- 125000002755 pyrazolinyl group Chemical group 0.000 abstract 1
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 1
- 125000002098 pyridazinyl group Chemical group 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 125000001422 pyrrolinyl group Chemical group 0.000 abstract 1
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000005493 quinolyl group Chemical group 0.000 abstract 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 230000002441 reversible effect Effects 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 abstract 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 abstract 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 abstract 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 abstract 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 abstract 1
- 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 125000001984 thiazolidinyl group Chemical group 0.000 abstract 1
- 125000002769 thiazolinyl group Chemical group 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 abstract 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03011305A EP1479676A1 (en) | 2003-05-19 | 2003-05-19 | Benzimidazole-derivatives as factor xa inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR045683A1 true AR045683A1 (es) | 2005-11-09 |
Family
ID=33040952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040101695A AR045683A1 (es) | 2003-05-19 | 2004-05-17 | Derivados de bencimidazol como inhibidores del factor xa |
Country Status (29)
| Country | Link |
|---|---|
| EP (2) | EP1479676A1 (enExample) |
| JP (1) | JP4658940B2 (enExample) |
| KR (1) | KR20060014056A (enExample) |
| CN (2) | CN101139346A (enExample) |
| AR (1) | AR045683A1 (enExample) |
| AT (1) | ATE474838T1 (enExample) |
| AU (1) | AU2004238497B2 (enExample) |
| BR (1) | BRPI0410446A (enExample) |
| CA (1) | CA2526065A1 (enExample) |
| CL (1) | CL2004001078A1 (enExample) |
| CR (1) | CR8087A (enExample) |
| DE (1) | DE602004028240D1 (enExample) |
| EC (1) | ECSP056178A (enExample) |
| MA (1) | MA27798A1 (enExample) |
| MX (1) | MXPA05012231A (enExample) |
| NO (1) | NO20055910L (enExample) |
| NZ (1) | NZ543670A (enExample) |
| OA (1) | OA13168A (enExample) |
| PA (1) | PA8603501A1 (enExample) |
| PE (1) | PE20050198A1 (enExample) |
| RS (1) | RS20050856A (enExample) |
| RU (1) | RU2346944C2 (enExample) |
| SA (1) | SA04250196B1 (enExample) |
| TN (1) | TNSN05297A1 (enExample) |
| TW (1) | TW200503696A (enExample) |
| UA (1) | UA82100C2 (enExample) |
| UY (1) | UY28324A1 (enExample) |
| WO (1) | WO2004101553A1 (enExample) |
| ZA (1) | ZA200508151B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10342570A1 (de) * | 2003-09-15 | 2005-04-14 | Bayer Healthcare Ag | Verfahren zur Herstellung von 4-(4-Aminophenyl)-3-morpholinon |
| US20060160799A1 (en) | 2004-04-23 | 2006-07-20 | Alekshun Michael N | Transcription factor modulating compounds and methods of use thereof |
| WO2008033739A2 (en) * | 2006-09-12 | 2008-03-20 | Neurogen Corporation | Benzimidazole carboxamide derivatives |
| DE102010018299A1 (de) | 2010-04-23 | 2011-10-27 | Archimica Gmbh | Verfahren zur Herstellung von 4-(4-Aminophenyl)-morpholin-3-on |
| CN105829293B (zh) * | 2013-12-20 | 2018-11-09 | 中国人民解放军军事医学科学院毒物药物研究所 | 新型哌啶氨甲酰类化合物、制备方法及其用途 |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| WO2019165374A1 (en) | 2018-02-26 | 2019-08-29 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds as hbv replication inhibitors |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1377642A (en) * | 1971-01-14 | 1974-12-18 | Koninklijke Gist Spiritus | Penicillanic and cephalosporanic acid derivatives |
| US4269846A (en) * | 1979-10-29 | 1981-05-26 | Usv Pharmaceutical Corporation | Heterocyclic compounds useful as anti-allergy agents |
| JPH0784462B2 (ja) * | 1986-07-25 | 1995-09-13 | 日清製粉株式会社 | ベンゾイミダゾ−ル誘導体 |
| US4897401A (en) * | 1987-06-19 | 1990-01-30 | Janssen Pharmaceutical N.V. | N-(4-piperidinyl) bicyclic condensed 2-imidazolamine derivatives useful in treating allergic diseases |
| DE3828537A1 (de) * | 1988-08-23 | 1990-03-01 | Basf Ag | Neue n-substituierte benzimidazol-2-carbonsaeureanilide, deren verwendung als lichtschutzmittel, insbesondere polymere und diese anilide enthaltendes organisches material |
| JPH0324609A (ja) * | 1989-06-21 | 1991-02-01 | Mitsuba Electric Mfg Co Ltd | Ｉ／ｏ用バッファｉｃ |
| JPH03184043A (ja) * | 1989-12-14 | 1991-08-12 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
| KR100190299B1 (ko) * | 1990-07-19 | 1999-06-01 | 디르크 반테 | 신규한 옥사졸릴 유도체 |
| DE4304650A1 (de) * | 1993-02-16 | 1994-08-18 | Thomae Gmbh Dr K | Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| SI9520096A (sl) * | 1994-09-30 | 1998-04-30 | Pfizer Inc. | Derivati 2,7-substituiranega oktahidro-1H-pirido /1,2-a/ pirazina |
| JPH08208640A (ja) * | 1995-02-06 | 1996-08-13 | Nisshin Flour Milling Co Ltd | ベンズイミダゾール誘導体およびそれを含有する心不全治療薬 |
| JPH08295667A (ja) * | 1995-04-27 | 1996-11-12 | Takeda Chem Ind Ltd | 複素環化合物、その製造法および剤 |
| JPH09124609A (ja) * | 1995-11-07 | 1997-05-13 | Nissan Chem Ind Ltd | ベンズイミダゾール誘導体 |
| JPH10182459A (ja) * | 1996-12-26 | 1998-07-07 | Otsuka Pharmaceut Co Ltd | ｃＧＭＰ分解酵素阻害剤 |
| UA62972C2 (en) * | 1997-07-03 | 2004-01-15 | Application of imidazopyrimidins and imidazopyridins for the treatment of neural disorders | |
| TR200002904T2 (tr) * | 1998-04-10 | 2001-02-21 | Japan Tobacco Inc. | Amidin bileşikleri |
| RS20050201A (sr) * | 2002-09-06 | 2007-06-04 | Janssen Pharmaceutica N.V., | Heterociklična jedinjenja |
-
2003
- 2003-05-19 EP EP03011305A patent/EP1479676A1/en not_active Withdrawn
-
2004
- 2004-05-03 PE PE2004000446A patent/PE20050198A1/es not_active Application Discontinuation
- 2004-05-05 RS YUP-2005/0856A patent/RS20050856A/sr unknown
- 2004-05-05 AU AU2004238497A patent/AU2004238497B2/en not_active Expired - Fee Related
- 2004-05-05 DE DE602004028240T patent/DE602004028240D1/de not_active Expired - Lifetime
- 2004-05-05 EP EP04731162A patent/EP1636216B1/en not_active Expired - Lifetime
- 2004-05-05 CA CA002526065A patent/CA2526065A1/en not_active Abandoned
- 2004-05-05 MX MXPA05012231A patent/MXPA05012231A/es active IP Right Grant
- 2004-05-05 AT AT04731162T patent/ATE474838T1/de not_active IP Right Cessation
- 2004-05-05 OA OA1200500322A patent/OA13168A/en unknown
- 2004-05-05 KR KR1020057022122A patent/KR20060014056A/ko not_active Ceased
- 2004-05-05 CN CNA2007101491602A patent/CN101139346A/zh active Pending
- 2004-05-05 BR BRPI0410446-3A patent/BRPI0410446A/pt not_active IP Right Cessation
- 2004-05-05 CN CNB2004800139377A patent/CN100484935C/zh not_active Expired - Fee Related
- 2004-05-05 WO PCT/EP2004/004750 patent/WO2004101553A1/en not_active Ceased
- 2004-05-05 JP JP2006529739A patent/JP4658940B2/ja not_active Expired - Fee Related
- 2004-05-05 RU RU2005139555/04A patent/RU2346944C2/ru not_active IP Right Cessation
- 2004-05-05 UA UAA200512138A patent/UA82100C2/uk unknown
- 2004-05-05 NZ NZ543670A patent/NZ543670A/en unknown
- 2004-05-17 TW TW093113795A patent/TW200503696A/zh unknown
- 2004-05-17 AR ARP040101695A patent/AR045683A1/es not_active Application Discontinuation
- 2004-05-17 CL CL200401078A patent/CL2004001078A1/es unknown
- 2004-05-19 UY UY28324A patent/UY28324A1/es unknown
- 2004-05-19 PA PA20048603501A patent/PA8603501A1/es unknown
- 2004-06-30 SA SA04250196A patent/SA04250196B1/ar unknown
-
2005
- 2005-10-10 ZA ZA200508151A patent/ZA200508151B/xx unknown
- 2005-11-08 MA MA28587A patent/MA27798A1/fr unknown
- 2005-11-11 CR CR8087A patent/CR8087A/es not_active Application Discontinuation
- 2005-11-18 EC EC2005006178A patent/ECSP056178A/es unknown
- 2005-11-18 TN TNP2005000297A patent/TNSN05297A1/en unknown
- 2005-12-13 NO NO20055910A patent/NO20055910L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009509989A5 (enExample) | ||
| AR070441A1 (es) | Clorotiofeno - amidas como inhibidores de los factores de coagulacion xa y trombina | |
| AU2017221865B2 (en) | Viral replication inhibitors | |
| AR042648A1 (es) | Derivados de pirazol como inhibidores del factor xa ******* no publicar ********** desistimiento voluntario ********** pasar a alejandra villoldo *********** | |
| ES2928147T3 (es) | Compuesto de 1H-imidazo[4,5-H]quinazolina como inhibidor de proteincinasas | |
| ES2320955B1 (es) | Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida. | |
| CA2981404C (en) | Rsv antiviral pyrazolo- and triazolo-pyrimidine compounds | |
| AR016702A1 (es) | Heteroaril aminoguanidinas y alcoxiguanidinas que actuan como inhibidores de las proteasas, composicion farmaceutica que las contiene, metodos in vitro deuso de las mismas, dispositivo que las emplea, y proceso para prepararlas. | |
| AR045683A1 (es) | Derivados de bencimidazol como inhibidores del factor xa | |
| AR061599A1 (es) | Nitrilos espirociclicos como inhibidores de proteasa | |
| JP2006528601A5 (enExample) | ||
| CN101321753A (zh) | 用于治疗痴呆和神经变性疾病的糖原合酶激酶3抑制剂的新咪唑并[4,5-b]吡啶衍生物 | |
| TW200413354A (en) | Substituted alkylamine derivatives and methods of use | |
| WO2012083053A2 (en) | Anti-viral compounds | |
| BR112015024552B1 (pt) | Composto, usos de um composto, composição farmacêutica, método para a preparação do composto e uso de uma quantidade eficaz de um composto | |
| WO2012083043A1 (en) | Anti-viral compounds | |
| WO2013028445A1 (en) | Fatty acid synthase inhibitors | |
| JP2011512368A5 (enExample) | ||
| CO6251238A2 (es) | Tetrahidrobenzo-1,4-diacepinas arilo - y heteroarilo - sustituidas y su uso para bloquear la recaptacion de norepinefrina dapamina y serotanina | |
| JP2010503625A5 (enExample) | ||
| JP2006528941A5 (enExample) | ||
| JP2011521981A5 (enExample) | ||
| JP2010511641A5 (enExample) | ||
| JP2010503624A5 (enExample) | ||
| ES2657979T3 (es) | Compuestos de imidazol como moduladores de FSHR y sus usos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |